Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Scale-Up Processes01:14

Scale-Up Processes

The scale-up of microbial fermentation processes is essential in industrial biotechnology, allowing the transition from laboratory-scale experiments to commercial-scale production while aiming to maintain product yield and quality. This process requires meticulous adjustment of equipment design, process parameters, and contamination control strategies to accommodate increasing culture volumes.At the laboratory scale, cultures are typically maintained in 1 to 10-liter glass or autoclavable...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct migration patterns of adult neural stem cells derived from hippocampal and ventricular niches.

Frontiers in aging neuroscience·2026
Same author

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
Same author

Association Between a History of Contact Sport Participation and Higher Lifetime Mild Traumatic Brain Injury Burden Among Military Servicemembers and Veterans: A Long-term Impact of Military-relevant Brain Injury Consortium-Chronic Effects of Neurotrauma Consortium Prospective Longitudinal Study (LIMBIC-PLS).

Orthopaedic journal of sports medicine·2026
Same author

A description of self-selected treatments and self-reported improvement following treatment among post-9/11 veterans experiencing disruptive dizziness following a comprehensive traumatic brain injury evaluation.

Brain injury·2026
Same author

"Just put the heart into it and go with the flow": Family preparedness for a good end-of-life for people with dementia from perspectives of active family caregivers and healthcare professionals in Vietnam.

The Gerontologist·2026
Same author

Systematic evaluation of transposon vector elements to establish high-producing stable CHO cell pools achieving > 10 g/L monoclonal antibody titers.

New biotechnology·2026

Related Experiment Video

Updated: May 21, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

A new large-scale manufacturing platform for complex biopharmaceuticals.

Jens H Vogel1, Huong Nguyen, Roberto Giovannini

  • 1Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California, USA.

Biotechnology and Bioengineering
|June 13, 2012
PubMed
Summary

A new integrated manufacturing platform improves biopharmaceutical production by reducing product residence time. This innovative approach enhances yield by 40% and ensures consistent product quality in large-scale commercial manufacturing.

More Related Videos

Large-Scale Cell Production Based on GMP-Grade Dissolvable Porous Microcarriers
09:44

Large-Scale Cell Production Based on GMP-Grade Dissolvable Porous Microcarriers

Published on: July 7, 2023

The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 21, 2026

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

Large-Scale Cell Production Based on GMP-Grade Dissolvable Porous Microcarriers
09:44

Large-Scale Cell Production Based on GMP-Grade Dissolvable Porous Microcarriers

Published on: July 7, 2023

The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

Area of Science:

  • Biopharmaceutical Manufacturing
  • Biotechnology
  • Chemical Engineering

Background:

  • Complex biopharmaceuticals, like recombinant blood coagulation factors, are vital for critical medical needs, driving a growing multibillion-dollar market.
  • Ensuring acceptable yields and high product quality for inherently unstable biopharmaceuticals necessitates minimizing their residence time in non-ideal manufacturing environments.
  • Continuous perfusion cell culture offers reduced bioreactor residence times but presents significant product recovery challenges requiring novel solutions.

Purpose of the Study:

  • To develop, scale-up, and implement an integrated manufacturing platform to maximize yield, process efficiency, and facility utilization for complex biopharmaceuticals.
  • To address the challenges of product recovery in continuous perfusion cell culture through innovative solutions.
  • To demonstrate the commercial viability and robustness of the new platform in Good Manufacturing Practice (GMP) settings.

Main Methods:

  • Developed and implemented an integrated manufacturing platform featuring semi-continuous cell separation with a disposable flow path, integrated with upstream perfusion.
  • Utilized large-scale adsorber capsules in rapid cycling mode for membrane chromatography in a bind/elute mode.
  • Applied the platform for commercial-scale manufacturing of a new product candidate.

Main Results:

  • Achieved a 40% yield improvement compared to conventional process technology for a new product candidate.
  • Demonstrated consistently high product quality.
  • Successfully processed over 1,000,000 L of cell culture harvest with a 100% success rate in GMP manufacturing.
  • Established the first commercial-scale application of membrane chromatography for bind/elute chromatography in the biopharmaceutical industry.

Conclusions:

  • The integrated manufacturing platform significantly enhances yield and product quality for complex biopharmaceuticals.
  • The platform demonstrates robustness and scalability for commercial GMP manufacturing.
  • The successful application of membrane chromatography in bind/elute mode represents a significant advancement for biopharmaceutical manufacturing, particularly for potent, low-dose products.